硬皮病相关间质性肺病患者治疗后咳嗽及咳嗽特异性生活质量改善:硬皮病肺研究II结果
本研究基于硬皮病肺研究II(N=142)的随机对照试验数据,比较霉酚酸酯(MMF)与口服环磷酰胺(CYC)治疗硬皮病相关间质性肺病(SSc-ILD)。基线时61.3%的患者报告频繁咳嗽,这些患者呼吸困难更重、高分辨率CT上间质性肺病范围更广、一氧化碳弥散量更低、胃食管反流病症状更多。咳嗽特异性生活质量(LCQ总分15.4±3.7,正常范围3-21,分数越高生活质量越差)轻度受损。2年内频繁咳嗽比例在CYC组下降44%、MMF组下降41%,且下降与胃食管反流病和间质性肺病严重程度的变化显著相关。作者认为频繁咳嗽可能作为SSc-ILD试验中治疗反应的替代标志物。
要点
- SSc-ILD患者基线频繁咳嗽发生率为61.3%,频繁咳嗽者呼吸困难更重、HRCT上ILD范围更广、DLCO更低、GERD症状更多。
- 频繁咳嗽者咳嗽特异性生活质量轻度受损,LCQ总分15.4±3.7(正常范围3-21,分数越高生活质量越差)。
- 2年内频繁咳嗽比例在CYC组下降44%、MMF组下降41%,下降与GERD和ILD严重程度的变化显著相关。
- 作者认为频繁咳嗽可能作为SSc-ILD试验中治疗反应的替代标志物。
适用人群与场景
- 纳入硬皮病肺研究II的SSc-ILD患者(N=142),随机接受MMF或口服CYC治疗。
处置流程与药物剂量
- MMF与口服CYC作为SSc-ILD的治疗方案进行比较,具体剂量、给药途径、频次和疗程原文未提及。
研究设计与关键结果
- 研究类型为随机对照试验(硬皮病肺研究II)的事后分析,样本量N=142,人群为SSc-ILD患者,干预为MMF vs 口服CYC。
- 基线频繁咳嗽发生率为61.3%;频繁咳嗽者呼吸困难更重、HRCT上ILD范围更广、DLCO更低、GERD症状更多。
- 频繁咳嗽者LCQ总分15.4±3.7(正常范围3-21,分数越高生活质量越差)。
- 2年内频繁咳嗽比例在CYC组下降44%、MMF组下降41%,下降与GERD和ILD严重程度的变化显著相关。
证据类型、等级与局限
- 证据类型:随机对照试验(硬皮病肺研究II)的分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为频繁咳嗽可能作为SSc-ILD试验中治疗反应的替代标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cough is a common symptom of scleroderma-related interstitial lung disease (SSc-ILD), but its relationship to other characteristics of SSc-ILD, impact on cough-specific quality of life (QoL), and response to therapy for SSc-ILD have not been well studied.
METHODS: We investigated frequent cough (FC) in patients with SSc-ILD (N = 142) enrolled in the Scleroderma Lung Study II, a randomized controlled trial comparing mycophenolate mofetil (MMF) and oral cyclophosphamide (CYC) as treatments for interstitial lung disease (ILD). We determined the impact of FC on QoL (Leicester Cough Questionnaire [LCQ]), evaluated the change in FC in response to treatment for SSc-ILD, and examined the relationship between gastroesophageal reflux disease (GERD) and cough during the trial.
RESULTS: Study participants who reported FC at baseline (61.3%) reported significantly more dyspnea, exhibited more extensive ILD on high-resolution CT, had a lower diffusing capacity for carbon monoxide, and reported more GERD symptoms than did those without FC. Cough-specific QoL was modestly impaired in patients with FC (total LCQ score, 15.4 ± 3.7; normal range, 3-21 [higher scores indicate worse QoL]). The proportion of patients with FC at baseline declined by 44% and 41% over 2 years in the CYC and MMF treatment arms, respectively, and this decline was significantly related to changes in GERD and ILD severity.
CONCLUSIONS: FC occurs commonly in SSc-ILD, correlates with both the presence and severity of GERD and ILD at baseline, and declines in parallel with improvements in both ILD and GERD over a 2-year course of therapy. Frequent cough might serve as a useful surrogate marker of treatment response in SSc-ILD trials.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00883129; URL: www.clinicaltrials.gov.
参考来源
- Tashkin DP, Volkmann ER, Tseng CH, et al. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. Chest. 2016. PMID: 28012804. doi:10.1016/j.chest.2016.11.052
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。